AIMS: The aims of this study were to review our 5-year experience with clinical FISH testing for TP63 rearrangements using both TP63 break-apart (BAP) and TBL1XR1/TP63 dual-fusion (D-FISH) probes to evaluate the frequency of TP63 rearrangements and the distribution of TBL1XR1 vs. alternate partner loci, and to assess whether both probe sets are necessary in all cases undergoing FISH testing. METHODS AND RESULTS: A retrospective review of the Mayo Clinic cytogenetic database identified 470 patients evaluated by FISH testing for TP63 rearrangements in formalin-fixed paraffin-embedded (FFPE) tissue using both BAP and D-FISH probes. Of these, 25 (5.3%) had TP63 rearrangements. All samples were being investigated for anaplastic large-cell lymphoma or other T cell lymphoma subtypes. A TBL1XR1 partner was identified by D-FISH in 12 (48%) of 25 cases. All cases positive by TBL1XR1/TP63 D-FISH were also positive by TP63 BAP FISH. CONCLUSION: This is the largest series of TP63 rearrangements to date. The frequency of positive results among cases referred to a large reference laboratory for TP63 FISH testing was 5.3%. Approximately half of TP63 rearrangements have a TBL1XR1 partner. TP63 BAP FISH testing is sufficient for up-front testing of FFPE tissue samples. However, because of the genomic proximity of the TP63 and TBL1XR1 loci, we recommend reflex TBL1XR1/TP63 D-FISH testing in positive and equivocal cases.
AIMS: The aims of this study were to review our 5-year experience with clinical FISH testing for TP63 rearrangements using both TP63 break-apart (BAP) and TBL1XR1/TP63 dual-fusion (D-FISH) probes to evaluate the frequency of TP63 rearrangements and the distribution of TBL1XR1 vs. alternate partner loci, and to assess whether both probe sets are necessary in all cases undergoing FISH testing. METHODS AND RESULTS: A retrospective review of the Mayo Clinic cytogenetic database identified 470 patients evaluated by FISH testing for TP63 rearrangements in formalin-fixed paraffin-embedded (FFPE) tissue using both BAP and D-FISH probes. Of these, 25 (5.3%) had TP63 rearrangements. All samples were being investigated for anaplastic large-cell lymphoma or other T cell lymphoma subtypes. A TBL1XR1 partner was identified by D-FISH in 12 (48%) of 25 cases. All cases positive by TBL1XR1/TP63D-FISH were also positive by TP63BAP FISH. CONCLUSION: This is the largest series of TP63 rearrangements to date. The frequency of positive results among cases referred to a large reference laboratory for TP63 FISH testing was 5.3%. Approximately half of TP63 rearrangements have a TBL1XR1 partner. TP63BAP FISH testing is sufficient for up-front testing of FFPE tissue samples. However, because of the genomic proximity of the TP63 and TBL1XR1 loci, we recommend reflex TBL1XR1/TP63D-FISH testing in positive and equivocal cases.
Authors: David W Scott; Karen L Mungall; Susana Ben-Neriah; Sanja Rogic; Ryan D Morin; Graham W Slack; King L Tan; Fong Chun Chan; Raymond S Lim; Joseph M Connors; Marco A Marra; Andrew J Mungall; Christian Steidl; Randy D Gascoyne Journal: Blood Date: 2012-04-11 Impact factor: 22.113
Authors: Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis Journal: Blood Date: 2010-10-28 Impact factor: 22.113
Authors: Xueju Wang; Rebecca L Boddicker; Surendra Dasari; Jagmohan S Sidhu; Marshall E Kadin; William R Macon; Stephen M Ansell; Rhett P Ketterling; Karen L Rech; Andrew L Feldman Journal: Hum Pathol Date: 2017-01-30 Impact factor: 3.466
Authors: Martin Bjerregård Pedersen; Stephen Jacques Hamilton-Dutoit; Knud Bendix; Rhett P Ketterling; Patrick P Bedroske; Ivy M Luoma; Christopher A Sattler; Rebecca L Boddicker; N Nora Bennani; Peter Nørgaard; Michael Boe Møller; Torben Steiniche; Francesco d'Amore; Andrew L Feldman Journal: Blood Date: 2017-05-18 Impact factor: 22.113
Authors: Marie-Christine Aubry; Anja Roden; Stephen J Murphy; George Vasmatzis; Sarah H Johnson; Faye R Harris; Geoffrey Halling; Ryan A Knudson; Rhett P Ketterling; Andrew L Feldman Journal: Mod Pathol Date: 2014-09-05 Impact factor: 7.842
Authors: Edgardo R Parrilla Castellar; Elaine S Jaffe; Jonathan W Said; Steven H Swerdlow; Rhett P Ketterling; Ryan A Knudson; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; George Vasmatzis; Sarah E Gibson; Sarah Ondrejka; Alina Nicolae; Karen L Grogg; Cristine Allmer; Kay M Ristow; Wyndham H Wilson; William R Macon; Mark E Law; James R Cerhan; Thomas M Habermann; Stephen M Ansell; Ahmet Dogan; Matthew J Maurer; Andrew L Feldman Journal: Blood Date: 2014-06-03 Impact factor: 22.113
Authors: George Vasmatzis; Sarah H Johnson; Ryan A Knudson; Rhett P Ketterling; Esteban Braggio; Rafael Fonseca; David S Viswanatha; Mark E Law; N Sertac Kip; Nazan Ozsan; Stefan K Grebe; Lori A Frederick; Bruce W Eckloff; E Aubrey Thompson; Marshall E Kadin; Dragana Milosevic; Julie C Porcher; Yan W Asmann; David I Smith; Irina V Kovtun; Stephen M Ansell; Ahmet Dogan; Andrew L Feldman Journal: Blood Date: 2012-08-01 Impact factor: 22.113
Authors: R N Chavan; A G Bridges; R A Knudson; R P Ketterling; N Comfere; D A Wada; C Torres-Cabala; D J DiCaudo; G Vasmatzis; M R Pittelkow; A L Feldman Journal: Blood Cancer J Date: 2014-10-17 Impact factor: 11.037
Authors: Nada Ahmed; Rhett P Ketterling; Grzegorz S Nowakowski; Surendra Dasari; Andrew L Feldman Journal: Histopathology Date: 2022-05-27 Impact factor: 7.778